Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo

Journal of Investigative Dermatology

Volumn 115, Issue 6, 2000, Pages 1082-1087

  Wagner, Stephan N ^a   Wagner, Christine ^a   Lührs, Petra ^b   Weimann, Tatjana K ^a   Kutil, Raphaela ^b   Goos, Manfred ^a   Stingl, Georg ^b   Schneeberger, Achim ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CTL; Gene therapy; In vivo animal models; Rodent; Tumor immunity

Indexed keywords

AUTOANTIBODY; GLYCOPROTEIN GP 100; MELANOMA ASSOCIATED ANTIGEN; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SPECIFICITY; FEMALE; GENE THERAPY; IMMUNIZATION; IN VIVO STUDY; MASTOCYTOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY;

EID: 0034523152     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00157.x     Document Type: Article

References (28)

1. A range of CD4 T cell tolerance: Partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis
2. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
3. Genetic vaccination with tyrosinase-related protein 2 causes melanoma eradication but not vitiligo
4. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
5. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells
6. Modulating the immune response to genetic immunization
7. A fail-safe mechanism for maintaining self-tolerance
8. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases
9. Murine tumor antigens: Is it worth the search?
10. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
11. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T-lymphocytes associated with in vivo tumor regression
12. Development of a DNA vaccine against malignant melanoma
13. gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self- reactive, tumoricidal T cells using high-affinity, altered peptide ligand
14. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4 (+) T lymphocytes
15. Inducing autoimmune disease to treat cancer
16. Cancer vaccines based on the identification of genes encoding cancer regression antigens
17. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
18. Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma
19. Gene vaccination: Plasmid DNA is more than just a blueprint
20. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations
21. Expression cloning of the cDNA encoding a melanoma-associated antigen recognized by monoclonal antibody HMB-45: Identification as melanocyte-specific Pmel 17 cDNA
22. Analysis of Pmel17/gp100 expression in primary human tissue specimens: Implications for melanoma immuno- and gene-therapy
23. Tumor immunity and autoimmunity induced by immunization with homologous DNA
24. Clonal analysis of differentiated function in animal cell cultures. I. Possible correlated maintenance of differentiated function and the diploid karyotype
25. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine
26. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART 1 or gp100 for cancer therapy
27. Cloning and characterization of the genes encoding the routine homulogues of the human melanoma antigens MART 1 and gp100